跳转至内容
Merck
CN

A0152000

乙酰半胱氨酸杂质C

European Pharmacopoeia (EP) Reference Standard

别名:

N,N′-二乙酰基-L-胱氨酸, NSC 203780

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C10H16N2O6S2
化学文摘社编号:
分子量:
324.37
MDL number:
UNSPSC Code:
41116107
EC Number:
226-911-5
NACRES:
NA.24
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

SMILES string

S(SCC(NC(=O)C)C(=O)O)CC(NC(=O)C)C(=O)O

InChI key

YTPQSLLEROSACP-UHFFFAOYSA-N

InChI

1S/C10H16N2O6S2/c1-5(13)11-7(9(15)16)3-19-20-4-8(10(17)18)12-6(2)14/h7-8H,3-4H2,1-2H3,(H,11,13)(H,12,14)(H,15,16)(H,17,18)

grade

pharmaceutical primary standard

API family

acetylcysteine

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

General description

本品按现行药典规定交付。所有为支持本产品而提供的信息,包括 SDS 和任何产品信息小册子,均由药典颁发机构制定和发布。

如需进一步信息和支持,请访问现行药典网站。

Application

本欧洲药典参考标准仅用于欧洲药典中明确规定的用途。不保证适用于任何其他用途,用户请自行负责。本标准品不适用于人类或动物使用。
用于制备参考溶液 (c),根据欧洲药典各论 0967,使用气相色谱法(通则 2.2.28)测试乙酰半胱氨酸中的相关物质。

Packaging

本品按照现行药典要求提供。有关当前单位数量,请见EDQM 参考目录

Other Notes

可能适用相应的销售限制。

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助,请联系 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Knut Pettersson et al.
Atherosclerosis, 196(1), 275-282 (2006-12-13)
To investigate if the immunomodulator drug DINAC (1) affects arterial dimensions in asymptomatic patients with hypercholesterolemia, (2) has effects on leucocyte markers of inflammation and (3) has in vitro effects on nitric oxide synthase (NOS) in human umbilical vein endothelial
M Wågberg et al.
The Journal of pharmacology and experimental therapeutics, 299(1), 76-82 (2001-09-19)
Oxidation of lipoprotein-derived lipids is generally accepted to be important in atherogenesis, and lipophilic antioxidants have been suggested as potential antiatherosclerotic agents. The antiatherogenic effects observed by certain antioxidants, especially probucol, in different animal models support this suggestion. There are
Acetylcysteine
European Pharmacopoeia Commission and European Directorate for the Quality of Medicines & Healthcare
European pharmacopoeia, 4900-4901 (2021)
S Boräng et al.
Gene, 271(2), 183-192 (2001-06-22)
In this study, we have applied and evaluated a modified cDNA representational difference analysis (RDA) protocol based on magnetic bead technology to study the molecular effects of a candidate drug (N,N'-diacetyl-L-cystine, DiNAC) in a model for atherosclerosis. Alterations in a
S Böhler et al.
Infusionstherapie (Basel, Switzerland), 15(2), 89-92 (1988-04-01)
In this study the question of whether N-N-diacetylcystine (DAC), which is more stable than N-acetylcysteine (AcCYS), may provide a useful cysteine source for parenteral nutrition was investigated. In in vitro studies the release of cysteine from DAC was measured. The

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持